Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2010

View Archived Issues

Clinical development of ChimeriVax-Dengue vaccine updated

EVX-001650 displays antipsychotic activity in mouse models related to schizophrenia

AC-430 confers protection in models of autoimmune and inflammatory conditions

Proof-of-concept secukinumab trial in ankylosing spondylitis meets primary endpoint

Exelixis divulges novel mTORC1 inhibitors

Aveo Pharma advances phase Ib tivozanib/capecitabine combination trial

Orban Biotech receives Qualifying Therapeutic Discovery grant for IBC-VS01 vaccine

Salvat licenses tarafenacin to Kwang Dong Pharma for OAB in South Korea

Morphotek and Hokkaido University join to evaluate amatuximab for pancreatic cancer

Decreased IGF-I levels may correlate with growth defects in newborns with cystic fibrosis

Bristol-Myers Squibb updates pipeline progress for Q3 of 2010

Ipsen Pharma identifies new imidazolidine-2,4-dione derivatives for prostate cancer

Banyu Pharma presents new peptide P518 receptor antagonists

Lumixex launches diagnostic xTAG CYP2D6 Kit in U.S.

Circassia's Toleromune House Dust Mite vaccine shows promise in phase II trial

Genzyme to sell diagnostics business to Sekisui Chemical

Astex Therapeutics claims new fibroblast growth factor receptor inhibitors

Errant Gene Therapeutics receives U.S. federal grant for Thalagen research

Advanced Life Sciences applies for FDA orphan drug status for ALS-886 in ARDS

Phytopharm advances phase II smilagenin trial in early-stage Parkinson's disease

New GlyT-1 inhibitors claimed by sanofi-aventis

Phase III APPRAISE-2 trial of apixaban in ACS discontinued

Reolysin to enter phase I trial in pediatric patients with solid tumors

FDA approves Xgeva for SRE prophylaxis in patients with bone metastases from solid tumors

Second interim RESTORE-CLI data analysis shows primary endpoints met

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...